Literature DB >> 34233942

Aducanumab, Amyloid Lowering, and Slowing of Alzheimer Disease.

Stephen Salloway1, Jeffrey Cummings2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34233942      PMCID： PMC8456361          DOI： 10.1212/WNL.0000000000012451

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   11.800


× No keyword cloud information.
  1 in total

1.  Donanemab in Early Alzheimer's Disease.

Authors:  Mark A Mintun; Albert C Lo; Cynthia Duggan Evans; Alette M Wessels; Paul A Ardayfio; Scott W Andersen; Sergey Shcherbinin; JonDavid Sparks; John R Sims; Miroslaw Brys; Liana G Apostolova; Stephen P Salloway; Daniel M Skovronsky
Journal:  N Engl J Med       Date:  2021-03-13       Impact factor: 91.245
  1 in total
  11 in total

1.  Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.

Authors:  Andreea L Turcu; Júlia Companys-Alemany; Matthew B Phillips; Dhilon S Patel; Christian Griñán-Ferré; M Isabel Loza; José M Brea; Belén Pérez; David Soto; Francesc X Sureda; Maria G Kurnikova; Jon W Johnson; Mercè Pallàs; Santiago Vázquez
Journal:  Eur J Med Chem       Date:  2022-04-08       Impact factor: 7.088

2.  Expedited regulatory product approval in the time of COVID-19.

Authors:  Gary D Novack
Journal:  Ocul Surf       Date:  2022-05-28       Impact factor: 6.268

Review 3.  The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.

Authors:  Eric Karran; Bart De Strooper
Journal:  Nat Rev Drug Discov       Date:  2022-02-17       Impact factor: 112.288

Review 4.  Neuropathology of Alzheimer's Disease.

Authors:  Jorge A Trejo-Lopez; Anthony T Yachnis; Stefan Prokop
Journal:  Neurotherapeutics       Date:  2021-11-02       Impact factor: 6.088

Review 5.  Advances in Recapitulating Alzheimer's Disease Phenotypes Using Human Induced Pluripotent Stem Cell-Based In Vitro Models.

Authors:  Md Fayad Hasan; Eugenia Trushina
Journal:  Brain Sci       Date:  2022-04-26

Review 6.  Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.

Authors:  Geetika Nehra; Bjoern Bauer; Anika M S Hartz
Journal:  Pharmacol Ther       Date:  2022-01-30       Impact factor: 13.400

7.  Amyloid-β42 stimulated hippocampal lactate release is coupled to glutamate uptake.

Authors:  Erin R Hascup; Lindsey N Sime; Mackenzie R Peck; Kevin N Hascup
Journal:  Sci Rep       Date:  2022-02-17       Impact factor: 4.379

Review 8.  Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer's Disease.

Authors:  Younghoon Seo; Hyemin Jang; Hyejoo Lee
Journal:  Life (Basel)       Date:  2022-02-12

9.  Practical Considerations in the Administration of Aducanumab for the Neurologist.

Authors:  Katherine Coerver; Melissa M Yu; Anelyssa D'Abreu; Marc Wasserman; Kavita V Nair
Journal:  Neurol Clin Pract       Date:  2022-04

10.  Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.

Authors:  Eleonora Lacorte; Antonio Ancidoni; Valerio Zaccaria; Giulia Remoli; Leonardo Tariciotti; Guido Bellomo; Francesco Sciancalepore; Massimo Corbo; Flavia L Lombardo; Ilaria Bacigalupo; Marco Canevelli; Paola Piscopo; Nicola Vanacore
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.